top of page

Search Results

Results found for "Jana Selent"

  • Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering of Receptor Selectivity | Dr. GPCR Ecosystem

    Cheloha builds nanobody-GPCR ligand conjugates that rescue weak peptides, engineer receptor selectivity And can selectivity for one receptor subtype be engineered without redesigning the ligand from scratch Conformation selectivity changes the duration of the signal PTH receptor exists in G-protein coupled Attaching a short PTH fragment to a PTHR1-selective nanobody produces a ligand selective for that subtype ; the same fragment attached to a PTHR2-selective nanobody redirects it entirely.

  • Pfleger: NanoBRET, Receptor Complexes, and the Translation of GPCR Pharmacology | Dr. GPCR Ecosystem

    Pfleger challenges a silent assumption embedded in most of them: that the time point chosen for each Understanding receptor complexes is where the next layer of selectivity and specificity in drug discovery with angiotensin and CCR2 receptors in cell-based systems, working through the logic of functional selectivity 32:26 Screening receptors in complexes, not in isolation 40:03 When cell biology reached the patient Selected

  • Debbie Hay: Class B GPCRs, RAMPs, and the Migraine Pharmacology Gap | Dr. GPCR Ecosystem

    Hay on class B GPCRs, RAMPs, and the selectivity problem in CGRP-targeted migraine therapies - what the The Erenumab Selectivity Problem Erenumab, the first monoclonal antibody approved against a GPCR complex are conformational and fine-grained, not structurally obvious, making ligand selectivity considerably , selective ligands, and bimolecular fluorescence complementation in vivo 26:42 Structural data and what Because we don't have selective ligands."

  • Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem

    John Streicher on how HSP90 flips direction between brain and spinal cord, why isoform-selective inhibitors Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid The "brain always wins" problem is solved by isoform selectivity, not by dose. With a non-selective HSP90 inhibitor given systemically, the brain effect dominates and pain relief is The route from "intrathecal only" to "oral pill" runs through isoform selectivity.

  • Eleonora Comeo: Fluorescent Ligands and the Pharmacology of Adenosine Receptors | Dr. GPCR Ecosystem

    And yet approved therapies that selectively target these receptors remain remarkably scarce. One reason is that selectivity in this family is not just a matter of receptor subtype. subtype pharmacology - the four subtypes, their G protein coupling profiles, and why ubiquity creates selectivity Comeo's work uses selective antagonist controls and NanoBRET-tagged receptor constructs to distinguish collaboration, and not fearing the unknown 54:44 The dopamine rush that keeps scientists coming back SELECTED

  • Gunnar Schulte: Frizzled Receptors and the GPCR Identity Question | Dr. GPCR Ecosystem

    frizzled subtypes, receptor conformational dynamics, and biosensor platforms for quantifying signaling selectivity — how the receptor may choose between disheveled and G-protein signaling through conformational selection Disheveled may regulate access to both G-protein and beta-catenin pathways through conformational selection Schulte's lab has preliminary evidence that disheveled undergoes conformational selection at the receptor strongest argument for GPCR identity 01:03:11 Career advice: explore widely, then commit to a niche Selected

  • Lin and Ball: GPCR Antibody Characterization and the Recombinant Shift | Dr. GPCR Ecosystem

    immunize against, how receptor family homology between targets like CXCR1 and CXCR2 makes immunogen selection At GeneTex, he oversees target selection, QA review, and scientific outreach, and serves as the direct problem - how it developed, why it persists, and what systematic characterization requires Immunogen selection GPCR Family Homology Makes Immunogen Selection the Deciding Variable Before a single rabbit is immunized Inside a company, you understand the full range of decisions - immunogen design, host selection, production

  • Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates | Dr. GPCR Ecosystem

    Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates Turning functional selectivity This phenomenon, receptor signaling bias or functional selectivity, is now recognized as a meaningful detect and quantify it using reliable functional assays, and discusses how these data can guide lead selection explanations of biased signaling and co-authored the widely-applied simple method for quantifying functional selectivity

  • Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem

    Her work has also explored receptor subtype selectivity and peptide-binding GPCRs, connecting structural Subtype Selectivity Emerges from Subtle Structural Differences Even closely related receptor subtypes Selected Quotes “Communication pathways connect the ligand-binding site to the intracellular signaling Applications to Receptor Selectivity Dr. Nivedha: After that, I extended this work to study subtype selectivity.

  • Qing Fan: Inside the Architecture of Class C GPCRs | Dr. GPCR Ecosystem

    Baclofen, a selective GABA-B agonist, is the only FDA-approved drug targeting this receptor. work on the mu opioid receptor by Kobilka, Gnäder, Roth, and Shokat as an illustration of what pathway-selective She acknowledges the field's more recent reassessment of how clean that selectivity actually is in vivo - Increasing diversity in science through mentorship, structured Q&A, and institutional commitment SELECTED And this feature opens more room for selecting a specific effect without also interfering with other

  • Dr. Robert F. Bruns | Dr. GPCR Ecosystem

    He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997 He supported the D1 PAM project in various roles from its inception in 2002 until selection of a clinical

  • Foord: Serendipity, RAMPs, And Industrial GPCR Pharmacology | Dr. GPCR Ecosystem

    the challenges of target validation, and the realities of industrial decision-making around receptor selectivity Drug Discovery Is Constrained by Selectivity, Safety, and Strategy . the CRLR binding pocket is shared across CGRP, amylin, and adrenomedullin receptors, small-molecule selectivity CRLR signaling. 18:00 — Industrial migraine programs, small-molecule CGRP antagonists, challenges with selectivity

  • Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem

    role at Orion Biotechnology, I work at the intersection of science and business, which includes target selection linking distinct signaling pathways with their physiological effects and may serve as the basis for more selective the Slosky Lab is now working to understand how the principles of receptor allosterism and functional selectivity

  • Yamina Berchiche: Beyond the Lab — From Chemokine Receptors to the Dr. GPCR Ecosystem | Dr. GPCR Ecosystem

    Scientific Themes of the Conversation Chemokine receptor redundancy and the shift toward functional selectivity binding CCR2B showed the opposite: distinct ligands activate distinct signaling outputs, and functional selectivity 09:00 A master's, old-school molecular biology, and an accelerated JBC paper 11:00 CCR2B, functional selectivity , funding, and what's next 46:53 Recording Brian Roth from a Prius — the closet-studio origin story Selected

  • Kathryn Livingston: Allosteric Opioid Modulators and Receptor Signaling Beyond the Membrane | Dr. GPCR Ecosystem

    Livingston's PhD research at the University of Michigan addressed this systematically - mapping selectivity investigated the first allosteric modulators of opioid receptors under Traynor, characterizing their selectivity Scientific Themes of the Conversation Allosteric modulation of opioid receptors - mechanism, selectivity 58 What both roles look like day-to-day 39:28 Three steps for PhDs and postdocs considering industry Selected

  • GPCR Weekly News | Dr. GPCR Ecosystem

    complete intelligence. iPSC-Derived GPCR Models — Terry Hébert Live April 16 April 8-14, 2026 GPCR Selectivity At the Receptor–Transducer Interface — Live April 9 with Bryan Roth April 2 - 7, 2026 Interpret GPCR Selectivity

  • Michel Bouvier: BRET, Biased Agonism, and the Tools That Changed GPCR Pharmacology | Dr. GPCR Ecosystem

    concept for rescuing misfolded GPCR mutants, and biosensor platforms that helped establish functional selectivity living cells Pharmacological chaperones and the concept of rescuing misfolded receptors Functional selectivity Every receptor his lab has studied was selected because it was the right model for a question that was mutations 40:19 Advice for junior scientists and the rewards of discovery 43:41 Closing reflections SELECTED

  • Dr. Lauren M. Slosky | Dr. GPCR Ecosystem

    linking distinct signaling pathways with their physiological effects and may serve as the basis for more selective the Slosky Lab is now working to understand how the principles of receptor allosterism and functional selectivity

  • Foundry for GPCR Organizations | Dr. GPCR Ecosystem

    . 👉 Book a Free 30-min Strategy Call Select your Challenge... ↑ Pick your challenge to see tailored into practical understanding you can apply to data interpretation, lead optimization, and candidate selection

  • Maria Waldhoer: Pharmacological Fingerprints and the Limits of Bias | Dr. GPCR Ecosystem

    The approach sits in deliberate tension with the prevailing vocabulary of bias factors and functional selectivity Functional selectivity has been in the vocabulary since her PhD years in Vienna. including the EU grant pitch in Brussels 01:01:53 — "You're only as good as the other people you're with" Selected

  • GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem

    What learning from “failed” screens can reveal about receptor pharmacology and species selectivity. industrial postdoctoral fellowship at GSK, where he entered the GPCR field and became proficient in aptamer selection

  • Yamina's Corner | Dr. GPCR Ecosystem

    Insights: Translate complex GPCR pharmacology into clear decisions for lead optimization and candidate selection Together, we clarify specific, measurable goals, from target validation and assay development to CRO selection Whether it's optimizing CRO selection, building robust internal capabilities, or translating complex

  • Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem

    Attendees will gain a technical understanding of probe design, selectivity, and validated applications The company's portfolio is built around high-affinity, selective fluorescent ligands for GPCRs, supporting

  • Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem

    membranes represent an untapped pharmacological frontier, and caged ligands offer a route to drugging them selectively lab developed caged ligands that cross the plasma membrane and are uncaged intracellularly, enabling selective moments that reshaped a career: dimers, nuclear GPCRs, and G-proteins as transcriptional regulators Selected

  • GPCR Retreat | Dr. GPCR Ecosystem

    Additionally, each symposium of the GPCR Retreat 2023 will include one trainee short talk selected from encouraged to register to the meeting and submit an abstract for consideration for the trainee symposia and selected

  • Kari Johnson: mGlu2, Addiction, and the Brain Circuits Alcohol Rewires | Dr. GPCR Ecosystem

    research follows this receptor from the bench to the behaving animal, using optogenetics and circuit-selective Johnson's lab has extended this using conditional knockout mice that allow selective deletion of mGlu2 scientists: let the biology lead the method 35:28 Diversity in STEM and who carries the labor of change SELECTED

  • David Gloriam: Orphan Receptors, GPCRDB, and the Data Revolution in GPCR Pharmacology | Dr. GPCR Ecosystem

    drug designed around biased agonism principles received regulatory approval, but its actual functional selectivity He described coaching sessions, national leadership courses, and the deliberate selection of mentors vision for GPCRDB 50:01 Career-defining moments, work-life balance, and advice for junior scientists SELECTED

  • Elva Zhao: G Protein Regulation and Biased Signaling at the GLP-1 Receptor | Dr. GPCR Ecosystem

    kinetic roles of RGS and GoLoco proteins Biased agonism at class B GPCRs - ligand-dependent pathway selectivity The insight that G protein regulatory proteins may shape the functional selectivity of GLP-1 agonists collaborations 57:58 Advice for trainees - staying curious, knowing your question, and talking to people Selected

  • Robert J. Lefkowitz: Beta-Adrenergic Receptors, the GPCR Family, and Fifty Years of Discovery | Dr. GPCR Ecosystem

    and the transmission of scientific taste — How the values that make a scientist effective — problem selection The strategic logic behind choosing beta-adrenergic receptors The selection of the beta-adrenergic system quiet relief, a pot of coffee, and one phone call to Brian 01:35:54 Work-life balance: an honest answer SELECTED

  • Dr. GPCR Podcast

    Strategic Partners Latest Podcast Episodes Select by Guest Name 2026-06-10 2026-04-29 2026-03-04 2025

bottom of page